2023
Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
2019
Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes
Hashemi DA, Brown-Joel ZO, Tkachenko E, Nelson CA, Noe MH, Imadojemu S, Vleugels RA, Mostaghimi A, Wanat KA, Rosenbach M. Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes. JAMA Dermatology 2019, 155: 455-459. PMID: 30785603, PMCID: PMC6523472, DOI: 10.1001/jamadermatol.2018.5635.Peer-Reviewed Original ResearchConceptsNecrobiosis lipoidicaClinical featuresThyroid diseaseDiagnosis of NLRare granulomatous conditionComorbidities of patientsMulticenter retrospective reviewElevated blood glucosePennsylvania Health SystemMassachusetts General HospitalNL lesionsNotable comorbiditiesMedical comorbiditiesMedian hemoglobinPatient demographicsMedian ageRetrospective reviewEpidemiologic characteristicsPathophysiologic characteristicsBiopsy statusGranulomatous conditionsCase reportFemale sexBlood glucoseRisk factors
2018
Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).
Halabi S, Dutta S, Tangen C, Rosenthal M, Petrylak D, Thompson I, Chi K, De Bono J, Fandi A, Araujo J, Eisenberger M, Logothetis C, Quinn D, Fizazi K, Higano C, George D, Morris M, Small E, Tannock I, Kelly W. Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2018, 36: lba5005-lba5005. DOI: 10.1200/jco.2018.36.18_suppl.lba5005.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerDocetaxel/prednisoneOverall survivalCaucasian manHazard ratioLymph nodesRisk factorsProstate cancerMedian overall survivalPerformance status 0Phase III trialsPooled hazard ratioShorter overall survivalIndividual patient dataProportional hazards modelAfrican American menStatus 0Primary endpointIII trialsMedian hemoglobinMedian ageLiver diseaseMultivariable analysisPrognostic importance
2015
Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study
Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, White NH, Group F. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatric Diabetes 2015, 17: 212-221. PMID: 25690268, PMCID: PMC4539288, DOI: 10.1111/pedi.12264.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetes educationGlycemic controlRecent-onset type 2 diabetesLow-density lipoprotein cholesterolBiochemical parametersCardiometabolic risk factorsDiagnosis of T2DBody mass indexShort-term improvementStandardized diabetes educationInsulin discontinuationTarget HbA1cCommon comorbiditiesInsulin therapyLipoprotein cholesterolMedian hemoglobinBlood pressureMedian ageT2D cohortMass indexTreatment optionsRisk factorsEarly treatmentOutcome measures
2014
1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil
Isaacsson P, Teixeira M, Scaranti M, Matutino A, Negrao M, Fraile N, Souza K, Yen C, Pinheiro G, Hoff P, G.C.. 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil. Annals Of Oncology 2014, 25: iv487. DOI: 10.1093/annonc/mdu353.5.Peer-Reviewed Original ResearchInfusional reactionsMedian body mass indexDefinitive treatment interruptionECOG PS 0Frequent primary siteIntravenous cytotoxic chemotherapyMedian lymphocyte countCells/mm3Body mass indexTreatment interruptionAdequate prophylaxisCytotoxic chemotherapyLymphocyte countMedian hemoglobinMetastatic diseaseSystemic treatmentMedian ageBack painMass indexChemotherapy infusionCancer CenterChemotherapy unitCommon signsOutpatient unitSevere reactions
2013
Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria
Parrish DD, Blevins M, Megazzini KM, Shepherd BE, Mohammed MY, Wester CW, Vermund SH, Aliyu MH. Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria. International Journal Of STD & AIDS 2013, 25: 355-359. PMID: 24104694, PMCID: PMC4385388, DOI: 10.1177/0956462413506887.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDrug Therapy, CombinationFemaleHemoglobinsHIV InfectionsHumansLinear ModelsMaleMiddle AgedNigeriaRetrospective StudiesReverse Transcriptase InhibitorsRural PopulationSocioeconomic FactorsTime FactorsTreatment OutcomeZidovudineConceptsBaseline hemoglobin levelCombination antiretroviral therapyHemoglobin levelsAntiretroviral therapyHemoglobin recoveryNon-pregnant adult patientsUse of zidovudineZidovudine-containing regimenZidovudine-containing regimensNorth Central NigeriaGroup of patientsRural North-Central NigeriaMeasures of hemoglobinZidovudine useBaseline hemoglobinAdult patientsMedian hemoglobinHemoglobin responseHIV-1PatientsZidovudineHemoglobin dataHemoglobinRegimensTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply